Skip to main content
SpringerLink
Log in

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B

  • Original Research Article
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

Abstract

Background

Chronic hepatitis B (CHB) virus infection is a major global healthcare problem. The recent introduction of entecavir in Australia for the treatment of CHB patients in the naive treatment setting has triggered significant optimism with regards to improved clinical outcomes for CHB patients.

Objective

To estimate, from an Australian healthcare perspective, the cost effectiveness of entecavir 0.5mg/day versus lamivudine 100mg/day in the treatment of CHB patients naive to nucleos(t)ide therapy.

Methods

A cost-utility analysis to project the clinical and economic outcomes associated with CHB disease and treatment was conducted by developing two decision-tree models specific to hepatitis B e antigen-positive (HBeAg+ve) and HBeAg−ve CHB patient subsets. This analysis was constructed using the Australian payer perspective of direct costs and outcomes, with indirect medical costs and lost productivity not being included. The study population comprised a hypothetical cohort of 1000 antiviral treatment-naive CHB patients who received either entecavir 0.5mg/day or lamivudine 100 mg/day at model entry. The population of patients used in this analysis was representative of those patients likely to receive initial antiviral therapy in clinical practice in Australia. The long-term cost effectiveness of entecavir compared with lamivudine in the first-line treatment of CHB patients was expressed as an incremental cost per life-year gained (LYG) or QALY gained.

Results

Results revealed that the availability of entecavir 0.5mg/day as part of the Australian hepatologist’s treatment armamentarium should result in significantly lower future rates of compensated cirrhosis (CC), decompensated cirrhosis (DC), and hepatocellular carcinoma (HCC) events (i.e. 54 fewer cases of CC, seven fewer cases of DC, and 20 fewer cases of HCC over the model’s timeframe for HBeAg+ve CHB patients, and 69 fewer cases of CC, eight fewer cases of DC and 25 fewer cases of HCC over the model’s timeframe for HBeAg−ve CHB patients). Compared with lamivudine 100 mg/day, entecavir 0.5 mg/day generated an estimated incremental cost per LYG of Australian dollars ($A, year 2006 values) 5046 and an estimated incremental cost per QALY of $A5952 in the HBeAg+ve CHB patient population, an estimated incremental cost per LYG of $A7063 and an estimated incremental cost per QALY of $A8003 in the HBeAg−ve CHB patient population, and an overall estimated incremental cost per LYG of $A5853 and an estimated incremental cost per QALY of $A6772 in the general CHB population.

Conclusion

The availability of entecavir in Australian clinical practice should make long-term suppression of hepatitis B virus replication increasingly attainable, resulting in fewer CHB sequelae, at an acceptable financial cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Fig. 3

Similar content being viewed by others

Notes

  1. 1Telbivudine is the most recent antiviral drug approved by the Pharmaceutical Benefits Advisory Committee (PBAC) for the treatment of CHB (PBS listed December 2008). However, telbivudine is not included in this analysis as the PBAC recommendation for telbivudine (HBeAg+ve CHB patients only) is narrower than that of entecavir and lamivudine (HBeAg+ve and HBeAg−ve CHB patients).

References

  1. Andre F. Hepatitis B: a comprehensive prevention, diagnosis and treatment program. Past, present and future. J Gastroenterol Hepatol 2004; 19: S1–4

    Article  PubMed  Google Scholar 

  2. Alter MJ. Epidemiology and prevention of hepatitis B. Sem Liver Dis 2003; 23: 39–46

    Article  Google Scholar 

  3. Williams A. Reduction in the hepatitis B related burden of disease: measuring the success of universal immunisation programs. Commun Dis Intell 2002; 26: 458–60

    Google Scholar 

  4. Dore G, Wallace J, Locarnini S, et al. Hepatitis B in Australia: responding to a diverse epidemic. ACT-HBV (Advancing the Clinical Treatment of Hepatitis B Virus) [online]. Available from URL: http://alliance.hepatitis.org.au/uploads/ACT_HBV.pdf [Accessed 2006 Jan 23]

  5. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleos(t)ide analogues for CHB: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 1618–28

    Article  PubMed  CAS  Google Scholar 

  6. Conjeevaram HS, Lok AS. Management of CHB. J Hepatol 2003; Suppl. 31: S90–103

    Google Scholar 

  7. Papatheodoridis GV, Hadziyannis SJ. Current management of CHB. Aliment Pharmacol Ther 2004; 19: 25–37

    Article  PubMed  CAS  Google Scholar 

  8. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with CHB enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527–32

    Article  PubMed  CAS  Google Scholar 

  9. Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004; 11: 439–42

    Article  PubMed  CAS  Google Scholar 

  10. Lavanchy D. Hepatitis B: viral epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97–107

    Article  PubMed  CAS  Google Scholar 

  11. Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Sem Liver Dis 2005; 25: 29–39

    Article  CAS  Google Scholar 

  12. Perrillo RP. Therapy of hepatitis B: viral suppression or eradication. Hepatology 2006; 43(2 Suppl. 1): S182–S193

    Article  PubMed  CAS  Google Scholar 

  13. Jacobson I. Hepatitis B: science and treatment. DDW 2005 Conference Report [online]. Available from URL: http://www.natap.org/2005/ddw/ddw.htm [Accessed 2006 Jan 23]

  14. Yim HJ, Lok AS. Natural history of CHB virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173–81

    Article  PubMed  CAS  Google Scholar 

  15. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. NEJM 2006; 354: 1001–10

    Article  PubMed  CAS  Google Scholar 

  16. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. NEJM 2006; 354: 1011–20

    Article  PubMed  CAS  Google Scholar 

  17. Yuan Y, Iloeje U, Hau J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008; 14: 21–33

    PubMed  Google Scholar 

  18. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security Program. Value Health 2008; 11(Suppl. 1): S11–22

    Article  PubMed  Google Scholar 

  19. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73

    Article  PubMed  CAS  Google Scholar 

  20. Iloeje UH, Yang SI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–86

    Article  PubMed  Google Scholar 

  21. EASL Jury. EASL International Consensus Conference on Hepatitis B: consensus Statement. J Hepatol 2003; 39: S3–25

    Article  Google Scholar 

  22. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472–89

    Article  PubMed  Google Scholar 

  23. Lok SF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507–39

    Article  PubMed  CAS  Google Scholar 

  24. Keeffe EB, Dieterich DT, Han SB, et al. A treatment algorithm for the management of CHB virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87–106

    Article  PubMed  CAS  Google Scholar 

  25. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBEAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039–49

    Article  PubMed  CAS  Google Scholar 

  26. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. J Hepatol 2006; 44: 1656–65

    Article  CAS  Google Scholar 

  27. Colonno RJ, Rose RE, Pokornowski K, et al. Four year assessment of entecavir resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007; 46(Suppl. 1): S294

    Article  Google Scholar 

  28. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrobial Agents Chemother 2004; 48: 3498–507

    Article  CAS  Google Scholar 

  29. Osiowy C, Heathcote J, Zoulim F, et al. Resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B [abstract]. Hepatology 2005; 42, S1 (p586A): 993

    Google Scholar 

  30. Lee Y, Suh D, Lim Y, et al. Emergence of rtA181V/Tand rtN236T mutations after 48 weeks of adefovir dipivoxil therapy in patients with lamivudine-resistant chronic hepatitis B [abstract]. Hepatology 2005; 42, S1 (p578A): 972

    Article  Google Scholar 

  31. Lee C, Yeon J, Hong S, et al. More frequent and earlier emergence of adefovir resistance mutations in lamivudine resistant patients treated with ADV compared to previously reported nucleos(t)ide-treatment naive patients [abstract]. Hepatology 2005; 42, S1 (p593A): 1009

    Article  Google Scholar 

  32. Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir at 5 years shows long term maintenance of high genetic barrier to hepatitis B virus resistance. APASL Oral Presentation 2008 [online]. Available from URL: http://natap.org/2008/HBV/032508_04.htm [Accessed 2006 Jan 23]

  33. Gish RG, Lok SS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg positive chronic hepatitis B. Gastroenterology 2007; 133: 1347–54

    Article  Google Scholar 

  34. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant CHB. Gastroenterology 2004; 126: 91–101

    Article  PubMed  CAS  Google Scholar 

  35. Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it’s time to get off! Antivir Ther 2004; 9: 145–8

    PubMed  CAS  Google Scholar 

  36. Bell SJ, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 2005; 32: 122–7

    Article  PubMed  CAS  Google Scholar 

  37. Yang HI, Iloeje UH, SU J, et al. Progression to decompensated cirrhosis in chronic hepatitis B virus infected persons is strongly associated with baseline viral load [poster]. 40th European Society for the Study of Liver Meeting; 2005 Apr 13-17; Paris. J Hepatol 2005; 42: 195

    Article  Google Scholar 

  38. Australian Bureau of Statistics (ABS). Life Tables, Australia, 2004-2006. ABS, cat. no. 3302.0.55.001[online]. Available from URL: http://www.ausstats.abs.gov.au/ausstats/abs@archive.nsf/0/A272A6537B9EFD9DCA25738D000F2323/$File/3302_0_55_001_2006.xls [Accessed 2008 Jun 18]

  39. Durand-Zaleski I, Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventative strategies. Med Decis Making 1994; 14: 98–103

    Article  PubMed  CAS  Google Scholar 

  40. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001; 48: 251–9

    Article  PubMed  CAS  Google Scholar 

  41. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886–95

    Article  PubMed  Google Scholar 

  42. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008; 11(3): 527–38

    Article  PubMed  Google Scholar 

  43. Australian Government Schedule of Pharmaceutical Benefits [online]. Available from URL: http://www.pbs.gov.au/html/industry/home [Accessed 2008 Jun 16]

  44. Butler JRG, Piank S, Korda RJ, et al. The direct cost of managing patients with CHB infection in Australia. J Clin Gastroenterol 2004; 30: 187–92

    Article  Google Scholar 

  45. Mohamed R, Desmond P, Dong-Jin S, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19: 958–69

    Article  PubMed  Google Scholar 

  46. O’sullivan BG, Gidding HF, Law M, et al. Estimates of CHB virus infection in Australia, 2000. Aust N Z J Pub Health 2004; 28: 212–6

    Google Scholar 

  47. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938–45

    Article  PubMed  Google Scholar 

  48. The Public Health Association of Australia. Hepatitis B vaccination [online]. Available from URL: http://www.phaa.net.au/policy/HepBF.htm [Accessed 2005 Oct]

  49. Department of Health and Aging. The Australian immunisation handbook. 8th ed., p. 130 [online]. Available from URL: http://www.immunise.health.gov.au/handbook.htm [Accessed 2005 Oct 19]

  50. Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 2663–8

    Article  PubMed  Google Scholar 

  51. Mommeja-Manin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309–19

    Article  Google Scholar 

  52. Ohata K, Hamasaki K, Toriyama K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with CHB virus infection. J Gastroenterol Hepatol 2004; 19: 670–5

    Article  PubMed  Google Scholar 

  53. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265–72

    Article  PubMed  CAS  Google Scholar 

  54. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol 2005; 16: 65–72

    PubMed  Google Scholar 

  55. Marco VD, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883–91

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Associate Professor Greg Dore (Head, Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, NSW, Australia) for his insightful comments regarding this manuscript.

This work was funded by Bristol-Myers Squibb Australia Pty Ltd. All authors are employees of Bristol-Myers Squibb. Ms Arnold, Dr Iloeje and Dr Cook own stock in Bristol-Myers Squibb.

Author information

Authors and Affiliations

  1. Bristol Myers Squibb Australia, 556 Princes Highway, Noble Park North, Victoria, 3174, Australia

    Elizabeth Arnold (Health Economics and Pricing Manager) & Greg Cook

  2. Bristol-Myers Squibb, Plainsboro, New Jersey, USA

    Yong Yuan

  3. Bristol-Myers Squibb, Wallingford, Connecticut, USA

    Uchenna Iloeje

Authors
  1. Elizabeth Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uchenna Iloeje
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Greg Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Arnold.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnold, E., Yuan, Y., Iloeje, U. et al. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 6, 231–246 (2008). https://doi.org/10.1007/BF03256136

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256136

Keywords

Search

Navigation